The RET proto-oncogene: a molecular therapeutic target in thyroid cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The RET proto-oncogene plays a critical role in various human diseases.
• Germline mutations in RET are linked to multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma.
• Rearranged forms of RET (RET/PTC) are found in sporadic and radiation-associated papillary thyroid carcinomas.

Purpose of the Study:

• To review the mechanisms of oncogenic activation of RET tyrosine kinase.
• To explore current therapeutic approaches for RET-associated cancers.
• To identify potential therapeutic targets within the RET signaling pathway.

Main Methods:

• Literature review of studies on RET proto-oncogene mutations and associated diseases.
• Analysis of research on therapeutic strategies for RET-driven cancers.
• Identification of key molecules in RET signaling pathways for potential drug development.

Main Results:

• RET mutations lead to oncogenic activation of RET tyrosine kinase through diverse mechanisms.
• Established therapies include tyrosine kinase inhibitors, gene therapy, and RNA interference.
• RET and its downstream signaling molecules represent promising targets for novel cancer therapeutics.

Conclusions:

• RET proto-oncogene mutations are implicated in a spectrum of human cancers.
• Targeted therapies are advancing the treatment of RET-associated malignancies.
• Further research into RET signaling pathways may yield more selective and effective cancer treatments.